30.71

3.33% 0.99

Alamar Biosciences Inc (ALMR)

Overview News Price History Financials Discussions Forecast

Alamar Biosciences Inc stock is traded at $30.71, with a volume of 255.20K. It is up +3.33% in the last 24 hours and down -4.45% over the past month. Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Previous Close:

$29.72

Open:

$29.65

24h Volume:

255.20K

Relative Volume:

0.31

Market Cap:

$2.13B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+21.48%

1M Performance:

-4.45%

6M Performance:

+26.53%

1Y Performance:

+0.00%

1-Day Range:

$28.61

$31.18

1-Week Range:

$25.27

$31.51

52-Week Range:

$18.84

$39.61

Alamar Biosciences Inc Stock (ALMR) Company Profile

Name

Alamar Biosciences Inc

Sector

Healthcare (1051)

Industry

Medical Devices (142)

Phone

510-626-9888

Address

47071 BAYSIDE PARKWAY, FREMONT

Employee

222

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

ALMR's Discussions on Twitter

Compare ALMR vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALMR Alamar Biosciences Inc	30.71	2.13B	0	0	0	0.00
ABT Abbott Laboratories	103.66	179.36B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	96.03	122.84B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	308.97	118.51B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	45.67	66.19B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	89.76	51.74B	6.30B	1.07B	1.09B	1.8406

Alamar Biosciences Inc Stock (ALMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-12-26	Initiated	BofA Securities	Neutral
May-12-26	Initiated	JP Morgan	Overweight
May-12-26	Initiated	Leerink Partners	Outperform
May-12-26	Initiated	Stifel	Buy
May-12-26	Initiated	TD Cowen	Buy

Alamar Biosciences Inc Stock (ALMR) Latest News

Oct 21, 2026

Form 4 Alamar Biosciences: Qiming Corporate GP VI, Ltd. (10% Owner) For: 19 October - Investing.com Canada

Oct 21, 2026

Oct 19, 2026

Four Qiming holders sold 173,673 Alamar Biosciences (ALMR) shares on October 15–16, 2026. - Stock Titan

Oct 19, 2026

Oct 15, 2026

Form 144 Alamar Biosciences For: 14 October By Investing.com - Investing.com Nigeria

Oct 15, 2026

Oct 14, 2026

Form 144 Alamar Biosciences For: 14 October By Investing.com - Investing.com UK

Oct 14, 2026

J.P. Morgan is broker for an affiliate’s proposed share sale at Alamar Biosciences (ALMR). - Stock Titan

Oct 14, 2026

An affiliate proposes selling 1.56M shares of Alamar Biosciences (Nasdaq: ALMR). - Stock Titan

Oct 14, 2026

An affiliate proposes selling 41,945 Alamar Biosciences (ALMR) shares through J.P. Morgan Securities LLC. - Stock Titan

Oct 14, 2026

Oct 13, 2026

Certain Class B Common Stock of Alamar Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2026. - www.marketscreener.com

Oct 13, 2026

Oct 05, 2026

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team - The Manila Times

Oct 05, 2026

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team - www.marketscreener.com

Oct 05, 2026

Sep 24, 2026

Alamar Biosciences Study in The Lancet Neurology Finds Distinct Biomarker Responses to Lecanemab in Early Alzheimer’s Disease - Quiver Quantitative

Sep 24, 2026

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment - GlobeNewswire Inc.

Sep 24, 2026

Sep 18, 2026

Why is Alamar Biosciences stock surging today? By Investing.com - Investing.com Nigeria

Sep 18, 2026

Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday - benzinga.com

Sep 18, 2026

Sep 04, 2026

Ragusa Robert P. Acquires 5,686 Shares and 25,599 Derivative Securities of Alamar Biosciences - Kalkine Media

Sep 04, 2026

Sep 03, 2026

Alamar Biosciences (ALMR) director has no reported share holdings - Stock Titan

Sep 03, 2026

Alamar Biosciences (ALMR) director gets new RSUs and stock option grant - Stock Titan

Sep 03, 2026

Sep 02, 2026

Alamar Biosciences Slides After Conference Hype Fades - TipRanks

Sep 02, 2026

Sep 01, 2026

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - manilatimes.net

Sep 01, 2026

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewswire

Sep 01, 2026

Alamar Biosciences, Inc. Announces Appointment of Robert Ragusa as Director and Member of Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, Effective September 1, 2026 - marketscreener.com

Sep 01, 2026

Aug 31, 2026

Alamar Biosciences expands proteomics partnership by 86,000 samples - Investing.com Nigeria

Aug 31, 2026

Aug 27, 2026

Valion Bio Announces Reverse Stock Split - Yahoo Finance

Aug 27, 2026

Aug 16, 2026

Alamar Biosciences Stock: Promising But Expensive Proteomics Growth (NASDAQ:ALMR) - Seeking Alpha

Aug 16, 2026

Aug 14, 2026

Alamar Stock: The Content Flywheel Is More Valuable Than The Instrument (ALMR) - Seeking Alpha

Aug 14, 2026

Aug 13, 2026

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure - Sahm

Aug 13, 2026

Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake - Stock Titan

Aug 13, 2026